Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 97

1.

Adherence to the National Quality Forum (NQF) breast cancer measures within cancer clinical trials: a review from ACOSOG Z0010.

Wilke LG, Ballman KV, McCall LM, Giuliano AE, Whitworth PW, Blumencranz PW, Reintgen DS, Burak WE, Leitch AM, Hunt KK.

Ann Surg Oncol. 2010 Aug;17(8):1989-94. doi: 10.1245/s10434-010-0980-9. Epub 2010 Mar 23.

2.

Patterns of participation and successful patient recruitment to American College of Surgeons Oncology Group Z0010, a phase II trial for patients with early-stage breast cancer.

Leitch AM, Beitsch PD, McCall LM, Posther K, Newman LA, Herndon JE 2nd, Hunt KK, Giuliano AE.

Am J Surg. 2005 Oct;190(4):539-42.

PMID:
16164916
3.

Update on the NSABP and ACOSOG breast cancer sentinel node trials.

White RL Jr, Wilke LG.

Am Surg. 2004 May;70(5):420-4. Review.

PMID:
15156950
4.

[Sentinel node biopsy in breast cancer: techniques and indications].

Haid A, Knauer M, Köberle-Wührer R, Wenzl E.

Wien Klin Wochenschr. 2005 Feb;117(4):121-8. Review. German.

PMID:
15847190
5.

Impact of the American College of Surgeons Oncology Group (ACOSOG) Z0011 trial on clinical management of the axilla in older breast cancer patients: a SEER-medicare analysis.

Caretta-Weyer H, Greenberg CG, Wilke LG, Weiss J, LoConte NK, Decker M, Steffens NM, Smith MA, Neuman HB.

Ann Surg Oncol. 2013 Dec;20(13):4145-52. doi: 10.1245/s10434-013-3193-1.

6.

Bone marrow micrometastases and adjuvant treatment of breast cancer.

Yu JJ, Brennan M, Christos P, Osborne MP, Hoda S, Simmons RM.

Breast J. 2004 May-Jun;10(3):181-5.

PMID:
15125741
7.

Survey of ASCO members on management of sentinel node micrometastases in breast cancer: variation in treatment recommendations according to specialty.

Wasif N, Ye X, Giuliano AE.

Ann Surg Oncol. 2009 Sep;16(9):2442-9. doi: 10.1245/s10434-009-0549-7. Epub 2009 Jun 9.

PMID:
19506955
8.

Sentinel node skills verification and surgeon performance: data from a multicenter clinical trial for early-stage breast cancer.

Posther KE, McCall LM, Blumencranz PW, Burak WE Jr, Beitsch PD, Hansen NM, Morrow M, Wilke LG, Herndon JE 2nd, Hunt KK, Giuliano AE.

Ann Surg. 2005 Oct;242(4):593-9; discussion 599-602.

9.

Are international guidelines for the prescription of adjuvant treatment for early breast cancer followed in clinical practice? Results of a population-based study on 1547 patients.

Palazzi M, De Tomasi D, D'Affronto C, Richetti A, Valli MC, Meregalli S, Asnaghi D, Arienti V, Cavallini D, Pradella R, Cafaro I, Baroncelli G, Di Lorenzo I, De Agostini A, Parrinello G, Bertoni F.

Tumori. 2002 Nov-Dec;88(6):503-6.

PMID:
12597147
10.
11.

Prognosis and treatment of patients with breast tumors of one centimeter or less and negative axillary lymph nodes.

Fisher B, Dignam J, Tan-Chiu E, Anderson S, Fisher ER, Wittliff JL, Wolmark N.

J Natl Cancer Inst. 2001 Jan 17;93(2):112-20.

PMID:
11208880
12.

Have the American College of Surgeons Oncology Group Z0011 trial results influenced the number of lymph nodes removed during sentinel lymph node dissection?

Robinson KA, Pockaj BA, Wasif N, Kaufman K, Gray RJ.

Am J Surg. 2014 Dec;208(6):1060-4; discussion 1063-4. doi: 10.1016/j.amjsurg.2014.08.009. Epub 2014 Oct 11.

PMID:
25312842
13.

Micrometastatic breast cancer cells in bone marrow at primary surgery: prognostic value in comparison with nodal status.

Diel IJ, Kaufmann M, Costa SD, Holle R, von Minckwitz G, Solomayer EF, Kaul S, Bastert G.

J Natl Cancer Inst. 1996 Nov 20;88(22):1652-8.

PMID:
8931609
14.

Florida Initiative for Quality Cancer Care: improvements in breast cancer quality indicators during a 3-year interval.

Laronga C, Gray JE, Siegel EM, Lee JH, Fulp WJ, Fletcher M, Schreiber F, Brown R, Levine R, Cartwright T, Abesada-Terk G Jr, Kim G, Alemany C, Faig D, Sharp P, Markham MJ, Shibata D, Malafa M, Jacobsen PB.

J Am Coll Surg. 2014 Oct;219(4):638-45.e1. doi: 10.1016/j.jamcollsurg.2014.03.063. Epub 2014 Jul 1.

15.

Sentinel-lymph-node biopsy in patients with breast cancer before and after neoadjuvant chemotherapy (SENTINA): a prospective, multicentre cohort study.

Kuehn T, Bauerfeind I, Fehm T, Fleige B, Hausschild M, Helms G, Lebeau A, Liedtke C, von Minckwitz G, Nekljudova V, Schmatloch S, Schrenk P, Staebler A, Untch M.

Lancet Oncol. 2013 Jun;14(7):609-18. doi: 10.1016/S1470-2045(13)70166-9. Epub 2013 May 15.

PMID:
23683750
16.

Applicability of the ACOSOG Z0011 criteria in women with high-risk node-positive breast cancer undergoing breast conserving surgery.

Chung A, Gangi A, Mirocha J, Giuliano A.

Ann Surg Oncol. 2015 Apr;22(4):1128-32. doi: 10.1245/s10434-014-4090-y. Epub 2014 Oct 10.

PMID:
25300606
17.
18.

Comparative analysis of bone marrow micrometastases with sentinel lymph node status in early-stage breast cancer.

Saha S, Ali S, Ghanem M, Soni M, Wiese D, Arora M, Singh T, Iddings D.

Ann Surg Oncol. 2009 Feb;16(2):276-80. doi: 10.1245/s10434-008-0244-0. Epub 2008 Dec 3.

PMID:
19050967
19.

Completion axillary lymph node dissection not required for regional control in patients with breast cancer who have micrometastases in a sentinel node.

Yegiyants S, Romero LM, Haigh PI, DiFronzo LA.

Arch Surg. 2010 Jun;145(6):564-9. doi: 10.1001/archsurg.2010.84.

PMID:
20566977
20.

Association of the presence of bone marrow micrometastases with the sentinel lymph node status in 410 early stage breast cancer patients: results of the Swiss Multicenter Study.

Langer I, Guller U, Koechli OR, Berclaz G, Singer G, Schaer G, Fehr MK, Hess T, Oertli D, Bronz L, Schnarwyler B, Wight E, Uehlinger U, Infanger E, Burger D, Zuber M; Swiss Multicenter Sentinel Lymph Node Study Group in Breast Cancer.

Ann Surg Oncol. 2007 Jun;14(6):1896-903. Epub 2007 Mar 14.

PMID:
17356955

Supplemental Content

Support Center